[{"id":"9cceceb2-4e58-41ef-ba8e-6eddd7740571","acronym":"","url":"https://clinicaltrials.gov/study/NCT05371054","created_at":"2022-05-12T15:56:31.055Z","updated_at":"2024-07-02T16:34:37.584Z","phase":"Phase 1/2","brief_title":"Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies","source_id_and_acronym":"NCT05371054","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • BCL2","pipe":" | ","alterations":" MYC rearrangement","tags":["ALK • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • prednisone • enitociclib (VIP152)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 04/05/2023","start_date":" 04/05/2023","primary_txt":" Primary completion: 03/10/2025","primary_completion_date":" 03/10/2025","study_txt":" Completion: 03/10/2025","study_completion_date":" 03/10/2025","last_update_posted":"2024-06-06"},{"id":"c9c366ea-e303-45e9-adda-89fe67d98af6","acronym":"VNC-152-101","url":"https://clinicaltrials.gov/study/NCT02635672","created_at":"2021-05-18T17:53:54.105Z","updated_at":"2024-07-02T16:35:39.904Z","phase":"Phase 1","brief_title":"Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer","source_id_and_acronym":"NCT02635672 - VNC-152-101","lead_sponsor":"Vincerx Pharma, Inc.","biomarkers":" MYC","pipe":" | ","alterations":" MYC amplification • MYC expression","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC amplification • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • enitociclib (VIP152)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 02/10/2016","start_date":" 02/10/2016","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-08-16"}]